TriNetX and Regeneron announced an agreement linking genomic and proteomic data for drug discovery and development, with TriNetX providing Regeneron exclusive, secure access to de-identified health data from about 300 million individuals. The deal is designed to support analytics and target identification by combining large real-world datasets with deeper molecular information. The framework positions TriNetX as an infrastructure provider to Regeneron’s R&D process, emphasizing licensed access and ongoing availability of both current and future datasets. For companies pursuing translational research, the partnership is a concrete example of data-scale sourcing to accelerate hypothesis generation. The move also intensifies competition in health-data aggregation and collaboration models, as more biopharma firms look to pair platform-level datasets with internal discovery programs.